A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma (NCT07258511)
A Phase 3 Randomized Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti CD38 Antibody
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic Phoenix — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (144 Sites)
Showing the first 25 of 144 sites.
- Mayo Clinic Phoenix — Phoenix, Arizona
- UAMS — Little Rock, Arkansas
- City of Hope Duarte — Duarte, California
- City of Hope Orange County Lennar Foundation Cancer Center — Irvine, California
- USC Norris Comprehensive Cancer Center — Los Angeles, California
- University of California San Francisco — San Francisco, California
- Colorado Blood Cancer Institute — Denver, Colorado
- University of Connecticut Health Center — Farmington, Connecticut
- Yale Cancer Center — New Haven, Connecticut
- Florida Cancer Specialists & Research Institute — Fort Myers, Florida
- Mayo Clinic Jacksonville — Jacksonville, Florida
- Moffit Cancer center — Tampa, Florida
- Emory University — Atlanta, Georgia
- City of Hope Chicago — Zion, Illinois
- University of Iowa Hospital and Clinics — Iowa City, Iowa
- Mission Cancer Blood — Waukee, Iowa
- University of Kansas Cancer Center — Kansas City, Kansas
- Norton Cancer Institute — Louisville, Kentucky
- University of Maryland School of Medicine — Baltimore, Maryland
- Mayo Clinic Rochester — Rochester, Minnesota
- Mount Sinai Brooklyn — Brooklyn, New York
- NYU Winthrop — Mineola, New York
- Mount Sinai Chelsea — New York, New York
- Laura and Isaac Perlmutter Cancer Center NYU ACC — New York, New York
- Icahn School of Medicine at Mount Sinai — New York, New York
📞 Contact the Study Coordinator
Phone: (844) 434-4210
Email: Participate-In-This-Study1@its.jnj.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Myeloma
- Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
- A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
- Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
- MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
- A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
- A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey
Explore by condition: All Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.